Breakthroughs in biomarkers, genetics, treatment modalities, and artificial intelligence are revolutionizing neuroscience R&D at a fast pace. These technological advancements are deepening our understanding of the biology of brain disorders, expanding the target landscape, and opening new avenues for transformative research, from small molecules to oligonucleotides, biologics to gene therapies.

At Lundbeck, we recognize that rapid innovation demands agility and adaptability to seize emerging opportunities, both internally and externally.

The External Innovation Unit within Lundbeck’s R&D is dedicated to fostering life science innovation through early stage, collaborative partnerships with biotech communities, industry leaders, and academic institutions. These alliances enable us to co-create the future of brain health, combining over 70 years of neuroscience expertise and R&D excellence, with external specialism and innovation.

Early-stage partnerships are central to Lundbeck’s approach. They allow us to exchange insights and expertise, creating shared value in the pursuit of common goals.  

• An integral part of our research matrix organization
• Driven by science and data – not just checking boxes
• Working close with our dedicated team of senior neuroscientists and drug hunters
• Considered members of our larger Lundbeck family

As a Focused Innovator, we actively pursue targets with well described biology for the highest likelihood of success. We put our strategic focus on partnerships across the respective fields of brain diseases within:  
 

• Neurology (neuro-rare, neuro-specialty field) 
• Psychiatry (rare) 

Our Research Strategy is biology driven and we operate within four specific biology clusters:

We explore new types of therapies, platforms and modalities, and areas of interest include (but are not limited to):

True innovation in neuroscience demands new tools and methods. That’s why we co-develop enabling technologies to support both discovery and therapeutic delivery. This could include: 

• Biomarker development – unlocking earlier diagnosis, patient stratification, and disease progression monitoring 
• Digital and data-driven science – leveraging AI, high-throughput screening, and real-world data to optimize therapeutic design and reduce development cycles 
• Advanced delivery platforms – enhancing CNS targeting, treatment adherence, and patient outcomes through new formulations and digital-health-enabled solutions  

A few examples of our currently ongoing Research partnerships include:

Lundbeck’s External Innovation Unit brings together the agility and curiosity of a biotech with the reach and rigor of a global neuroscience specialist.

We aspire to co-create transformative ideas and therapies that address some of the world’s most challenging brain disorders. We aim to bridge gaps across the R&D continuum by connecting visionary ideas with deep scientific and clinical expertise - accelerating innovation from early discovery to patient impact. 

Lundbeck’s External Research & Innovation unit is open for a dialog. If you are working on groundbreaking ideas in brain health - from molecular discoveries to digital solutions - let’s explore how we can bring them to patients, together.